Ryan Allway December 14th, 2020 Psychedelics MindMed (NEO: MMED, OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of lysergic acid diethylamide (LSD) assisted therapy... Read more

Ryan Allway December 14th, 2020 Psychedelics Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (“Havn Life”), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, is pleased to announce the first preclinical study to focus on the effects of psilocybin on the immune system,... Read more

Ryan Allway December 14th, 2020 Psychedelics Cybin Inc. (NEO:CYBN) (“Cybin”), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has closed on its acquisition of 100% of the shares in Adelia Therapeutics Inc. (“Adelia”) for up to CDN$20,161,575 (approximately USD$15.75 million) (the “Transaction”).... Read more

Ryan Allway December 14th, 2020 Psychedelics Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland“), and Disruptive Pharma, a Latin American focused pharmaceutical investment company, are pleased to announce they have entered into a non-binding letter of intent for the purposes of creating a joint... Read more

Ryan Allway December 10th, 2020 Psychedelics PharmaTher Inc., (“PharmaTher”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that it has been granted a Pre-Investigational New Drug... Read more

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more

Ryan Allway December 10th, 2020 Psychedelics Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (DTC: MCURF) (“Mind Cure”) is pleased today to announce its plans to open the first Mind Cure Health Center, which will offer psychedelic-assisted mental health therapy to patients as well as training to... Read more

Ryan Allway December 10th, 2020 Psychedelics Field Trip Health Ltd. (“Field Trip” or the “Company“) (CSE: FTRP) (OTCBB: FTRPF), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has agreed with Stifel Nicolaus Canada Inc. (“Stifel GMP” or the “Lead Underwriter“) as... Read more

Ryan Allway December 10th, 2020 Psychedelics BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech focused on the development and commercialization of revolutionary treatments, today announced the signing of a definitive agreement to acquire 100% of the assets in Transcend... Read more